Fed­er­al court judge rules in fa­vor of Ot­suka's Tai­ho in Lon­surf patent suit

A Delaware fed­er­al judge ruled Tues­day that the patent for Tai­ho On­col­o­gy’s can­cer drug Lon­surf will con­tin­ue to be up­held for an­oth­er six years, notch­ing a win for the Ot­su­ka unit.

Lon­surf is ap­proved alone and in com­bi­na­tion with oth­er drugs for the treat­ment of metasta­t­ic col­orec­tal can­cer (mCRC).

Tai­ho sued sev­er­al US- and In­dia-based gener­ics mak­ers be­gin­ning in 2019, in­clud­ing Eu­gia Phar­ma Spe­cial­ties, In­tas Phar­ma­ceu­ti­cals, Ac­cord Health­care, MSN Lab­o­ra­to­ries and Nat­co Phar­ma, af­ter they filed AN­DAs for a gener­ic ver­sion of the drug with the FDA.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER